



MEDIA RELEASE

For release November 1, 2009

Innovascreen hires Director, Business Development

HALIFAX, NOVA SCOTIA, CANADA – NOVEMBER 1st, 2009 -- Innovascreen announced today the hiring of Mr. Jeffrey Skinner as Director of Business Development. In this role, Jeff will be responsible for all negotiation and partnerships as well as lead Innovascreen's efforts to raise money in 2010.

"Jeff has the experience in identifying and closing partnerships deals that we require as our technology moves towards proof of concept," said Dr. John Lewis, President and CEO of Innovascreen. "We are excited to start this new phase of our corporate development.

Mr. Skinner has 10 years of experience in both the biotech and pharmaceutical industry specifically in Business Development. Mr. Skinner has led negotiations for large and small licensing deals of both early and late stage technologies. He also led the efforts for a small Canadian Based Biotech company to develop important collaborations in an effort to expand use of proprietary technologies. He has a BSc in Genetics and an MBA, both from the University of Western Ontario.

About Innovascreen

With two platform technologies under management, Innovascreen is an ideal partner for an organization involved in early stage preclinical development of therapeutic candidates. The Avian System for Evaluating Therapeutics (ASET) Platform allows our clients and partners to screen compound libraries and validates lead candidates for further investment, faster, better and cheaper than other available options. Fusogenix is an advanced drug delivery platform with a unique mechanism of action that offers the chance to improve systemic delivery of therapeutic cargos. Innovascreen is a privately held company, headquartered in Nova Scotia, Canada. For more information, please visit www.innovascreen.com

Contact:

Jeff Skinner,
Director, Business Development, Innovascreen, Inc
(902) 482-3832 x 7, jeff.skinner@innovascreen.com